Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

ABSTRACT: Background: Immunogenicity and safety of the AZD1222 (ChAdOx1 nCoV-19) vaccine was evaluated in Japanese adults in an ongoing phase 1/2, randomized, double-blind, parallel-group, placebo-controlled, multi-centre trial (NCT04568031). Methods: Adults (n=256, age ≥18 years) seronegative for...

Full description

Bibliographic Details
Main Authors:	Michiko Asano, Hiroshi Okada, Yohji Itoh, Hajime Hirata, Kensuke Ishikawa, Erika Yoshida, Akiko Matsui, Elizabeth J. Kelly, Kathryn Shoemaker, Urban Olsson, Johan Vekemans
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	International Journal of Infectious Diseases
Subjects:	COVID-19 ChAdOx1 nCoV-19 AZD1222 Japan Elderly adult Humoral response
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971221008183

Similar Items

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
by: Piyarat Limpawittayakul, et al.
Published: (2022-11-01)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023-01-01)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01)

SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19)
by: Richard Stebbings, et al.
Published: (2022-04-01)

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
by: Nussara Pakvisal, et al.
Published: (2022-11-01)

Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States
by: Abanoub Riad, et al.
Published: (2021-06-01)

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
by: Prasad S. Kulkarni, et al.
Published: (2024-12-01)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
by: Md. Altamash Ahmad, et al.
Published: (2023-03-01)

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
by: Jill Maaske, et al.
Published: (2023-01-01)

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield<sup>TM</sup>) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
by: Sharan Murali, et al.
Published: (2022-06-01)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
by: Kriangkrai Tawinprai, et al.
Published: (2022-01-01)

Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
by: Sang Won Lee, et al.
Published: (2021-09-01)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
by: Jer-Hwa Chang, et al.
Published: (2022-02-01)

A Systematic Review on the SARS CoV-2 Viral Vector Vaccine “Astrazeneca (Azd1222)”
by: rohama zahid, et al.
Published: (2022-06-01)

Fatal myositis, rhabdomyolysis and compartment syndrome after ChAdOx1 nCoV-19 vaccination
by: Szu-Ting Huang, et al.
Published: (2022-12-01)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
by: Jinnam Kim, et al.
Published: (2023-04-01)

Effectiveness of the chAdOx1 nCoV-19 vaccine in preventing COVID-19 infection
by: Tarana Sarwat, et al.
Published: (2022-01-01)

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
by: Jie Wei, et al.
Published: (2023-02-01)

Antibody Response against SARS-CoV-2 Following ChAdOx1(Astezeneca AZD 1222) Vaccine in Health Care Workers in a Tertiary Care Hospital in India
by: Felice FAIZAL, et al.
Published: (2021-09-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
by: Tamara Garibashvili, et al.
Published: (2022-06-01)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
by: Chandima Jeewandara, et al.
Published: (2022-04-01)

Acute Polyserositis with Cardiac Tamponade and Bilateral Refractory Pleural Effusion after ChAdOx1 nCoV-19 Vaccination
by: Guan-Yi Li, et al.
Published: (2022-08-01)

Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers
by: Hamed Zare, et al.
Published: (2022-10-01)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
by: Thachanun Porntharukchareon, et al.
Published: (2023-08-01)

Case report: Early onset Marin-Amat syndrome after receiving ChAdOx1 nCoV-19 vaccination
by: Ping-Feng Tsai, et al.
Published: (2022-11-01)

Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia
by: Victoria Panagiota, et al.
Published: (2022-08-01)

Relapse of immune thrombocytopenia after receiving AstraZeneca coronavirus disease‐2019 vaccine: A case report
by: Saba Seyedi, et al.
Published: (2023-09-01)

Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2– seropositive individuals
by: Edgar Ruz Fernandes, PhD, et al.
Published: (2023-05-01)

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)
by: Marisa Muadchimkaew, et al.
Published: (2022-11-01)

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
by: Minji Jeon, et al.
Published: (2021-09-01)

A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy
by: Raffaele Palladino, et al.
Published: (2021-06-01)

ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis
by: Wisit Prasithsirikul, et al.
Published: (2022-06-01)

Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study
by: Nattaya Teeyapun, et al.
Published: (2022-10-01)

Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2
by: Marlene Plüß, et al.
Published: (2022-01-01)

Active surveillance of adverse events following ChAdOx1 nCoV-19 immunization in geriatric population: a prospective multi-centric study from Jaipur, Rajasthan, India
by: Anil Bhandari, et al.
Published: (2022-01-01)

Covid Antibody Titers in Cancer Patients Following Vaccination with ChAdOx1 nCOV-19 Vaccine
by: Ashish Chavan, et al.

Antibody Response to ChAdOx1-nCoV-19 Vaccine Among Recipients in Bangladesh: A Prospective Observational Study
by: Hoque A, et al.
Published: (2021-12-01)

ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago
by: Chavin D. Gopaul, et al.
Published: (2022-03-01)

Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 nCoV-19 Vaccine
by: Pawita Suwanwattana, et al.
Published: (2023-06-01)